You have accessJournal of UrologyProstate Cancer: Detection and Screening IV1 Apr 20102097 RISING HOSPITAL ADMISSION RATES FOR UROLOGIC COMPLICATIONS AFTER TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BIOPSY Robert Nam, Laurence Klotz, Andrew Loblaw, John Trachtenberg, Andrew Simor, Aleksandra Stanimirovic, and Steven Narod Robert NamRobert Nam More articles by this author , Laurence KlotzLaurence Klotz More articles by this author , Andrew LoblawAndrew Loblaw More articles by this author , John TrachtenbergJohn Trachtenberg More articles by this author , Andrew SimorAndrew Simor More articles by this author , Aleksandra StanimirovicAleksandra Stanimirovic More articles by this author , and Steven NarodSteven Narod More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.02.2171AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Transrectal ultrasound (TRUS)-guided prostate biopsy is widely used to confirm the diagnosis of prostate cancer. The technique has been associated with significant morbidity in a small proportion of patients. METHODS We conducted a population-based study of 75,190 men who underwent a TRUS-guided biopsy in Ontario, Canada, between 1996 and 2005. We used hospital and cancer registry administrative databases to estimate the rates of hospital admission and mortality due to urologic complications associated with the procedure. RESULTS Of the 75,190 men who underwent a TRUS biopsy, 33,508 (44.6%) were diagnosed with prostate cancer and 41,682 (55.4%) did not have prostate cancer. The hospital admission rate for urologic complications within 30 days of the procedure for men without cancer was 1.9% (781/41,482). The 30-day hospital admission rate rose from 1.0% in 1996 to 4.1% in 2005 (p-value for trend <0.0001). The majority of hospital admissions (72%) were for infection-related reasons. The probability of being admitted to hospital within 30 days of having the procedure rose four-fold between 1996 and 2005 (odds ratio = 3.7; 95% C.I.: 2.0 – 7.0, p<0.0001). The overall 30-day mortality rate was 0.09%, but did not change over the study period. CONCLUSIONS The hospital admission rates for complications following a TRUS-guided prostate biopsy have risen dramatically over the last ten years, primarily due to an increasing rate of infection-related complications. Toronto, Canada© 2010 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byPearle M (2018) Should We Change Our Prophylactic Antimicrobial Regimen for Prostate Biopsy?Journal of Urology, VOL. 185, NO. 4, (1181-1183), Online publication date: 1-Apr-2011. Volume 183Issue 4SApril 2010Page: e815 Advertisement Copyright & Permissions© 2010 by American Urological Association Education and Research, Inc.MetricsAuthor Information Robert Nam More articles by this author Laurence Klotz More articles by this author Andrew Loblaw More articles by this author John Trachtenberg More articles by this author Andrew Simor More articles by this author Aleksandra Stanimirovic More articles by this author Steven Narod More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...